Antioxidant and vitamin e transport genes and risk of high-grade prostate cancer and prostate cancer recurrence

Prostate

Volumn 73, Issue 16, 2013, Pages 1786-1795

  Bauer, Scott R ^a   Richman, Erin L ^a   Sosa, Eduardo ^b   Weinberg, Vivian ^c   Song, Xiaoling ^d   Witte, John S ^a,b,c   Carroll, Peter R ^b,c   Chan, June M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d USA   (United States)

Author keywords

genetic polymorphisms; Gleason grade; prostate cancer; recurrence; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; COPPER ZINC SUPEROXIDE DISMUTASE; EXTRACELLULAR SUPEROXIDE DISMUTASE; GAMMA TOCOPHEROL; GENOMIC DNA; MANGANESE SUPEROXIDE DISMUTASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; GENETIC ASSOCIATION; GENOTYPE; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

GENETIC POLYMORPHISMS; GLEASON GRADE; PROSTATE CANCER; RECURRENCE; VITAMIN E;

AGED; ALPHA-TOCOPHEROL; CARRIER PROTEINS; GAMMA-TOCOPHEROL; HUMANS; LIPOPROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SUPEROXIDE DISMUTASE; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; VITAMIN E;

EID: 84886951960     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22717     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62 (1): 10-29.
2. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL,. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999; 8 (10): 893-899.
3. Rodriguez C, Jacobs EJ, Mondul AM, Calle EE, McCullough ML, Thun MJ,. Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol Biomarkers Prev 2004; 13 (3): 378-382.
4. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U,. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 2006; 98 (4): 245-254.
5. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK,. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90 (6): 440-446.
6. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD, Buring JE,. Vitamins E and C in the prevention of prostate and total cancer in men: The Physicians' Health Study II randomized controlled trial. JAMA 2009; 301 (1): 52-62.
7. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD III, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301 (1): 39-51.
8. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH,. Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306 (14): 1549-1556.
9. Oberley LW, Buettner GR,. Role of superoxide dismutase in cancer: A review. Cancer Res 1979; 39 (4): 1141-1149.
10. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD,. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000; 89 (1): 123-134.
11. Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY, Hayes RB,. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 2007; 16 (8): 1581-1586.
12. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J,. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005; 65 (6): 2498-2504.
13. Zimmer S, Stocker A, Sarbolouki MN, Spycher SE, Sassoon J, Azzi A,. A novel human tocopherol-associated protein: Cloning, in vitro expression, and characterization. J Biol Chem 2000; 275 (33): 25672-25680.
14. Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, Arai H, Inoue K,. Affinity for alpha-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett 1997; 409 (1): 105-108.
15. Wright ME, Peters U, Gunter MJ, Moore SC, Lawson KA, Yeager M, Weinstein SJ, Snyder K, Virtamo J, Albanes D,. Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk. Cancer Res 2009; 69 (4): 1429-1438.
16. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280 (11): 969-974.
17. Cooperberg MR, Hilton JF, Carroll PR,. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011; 117 (22): 5039-5046.
18. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR,. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173 (6): 1938-1942.
19. Willett W,. Nutritional epidemiology, 2nd edition. New York: Oxford University Press; 1998.
20. Weinstein SJ, Peters U, Ahn J, Friesen MD, Riboli E, Hayes RB, Albanes D,. Serum alpha-tocopherol and gamma-tocopherol concentrations and prostate cancer risk in the PLCO screening trial: A nested case-control study. PLoS ONE 2012; 7 (7): e40204.
21. Cheng TY, Barnett MJ, Kristal AR, Ambrosone CB, King IB, Thornquist MD, Goodman GE, Neuhouser ML,. Genetic variation in myeloperoxidase modifies the association of serum alpha-tocopherol with aggressive prostate cancer among current smokers. J Nutr 2011; 141 (9): 1731-1737.
22. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW,. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000; 92 (24): 2018-2023.
23. Huang HY, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ,. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 2003; 157 (4): 335-344.
24. Beilby J, Ambrosini GL, Rossi E, de Klerk NH, Musk AW,. Serum levels of folate, lycopene, beta-carotene, retinol and vitamin E and prostate cancer risk. Eur J Clin Nutr 2010; 64 (10): 1235-1238.
25. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, Stampfer MJ,. Lower prostate cancer risk in men with elevated plasma lycopene levels: Results of a prospective analysis. Cancer Res 1999; 59 (6): 1225-1230.
26. Gill JK, Franke AA, Steven Morris J, Cooney RV, Wilkens LR, Le Marchand L, Goodman MT, Henderson BE, Kolonel LN,. Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: The multiethnic cohort. Cancer Causes Control 2009; 20 (7): 1161-1171.
27. Goodman GE, Schaffer S, Omenn GS, Chen C, King I,. The association between lung and prostate cancer risk, and serum micronutrients: Results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev 2003; 12 (6): 518-526.
28. Karppi J, Kurl S, Laukkanen JA, Kauhanen J,. Serum beta-carotene in relation to risk of prostate cancer: The Kuopio Ischaemic Heart Disease Risk Factor study. Nutr Cancer 2012; 64 (3): 361-367.
29. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E,. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 2007; 86 (3): 672-681.
30. Nomura AM, Stemmermann GN, Lee J, Craft NE,. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1997; 6 (7): 487-491.
31. Wright ME, Weinstein SJ, Lawson KA, Albanes D, Subar AF, Dixon LB, Mouw T, Schatzkin A, Leitzmann MF,. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2007; 16 (6): 1128-1135.
32. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM,. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 2011; 107 (1): 126-134.
33. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW,. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 2009; 27 (22): 3577-3583.
34. Crawford A, Fassett RG, Geraghty DP, Kunde DA, Ball MJ, Robertson IK, Coombes JS,. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene 2012; 501 (2): 89-103.
35. Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D,. Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 2003; 14 (6): 513-518.
36. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW Jr, Giovannucci E,. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 2008; 29 (12): 2335-2340.
37. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK,. Oxidative stress in prostate cancer. Cancer Lett 2009; 282 (2): 125-136.
38. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK,. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68 (6): 1777-1785.
39. Huang WC, Li X, Liu J, Lin J, Chung LW,. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 2012; 10 (1): 133-142.
40. Rajendran M, Thomes P, Zhang L, Veeramani S, Lin MF,. p66Shc-A longevity redox protein in human prostate cancer progression and metastasis: p66Shc in cancer progression and metastasis. Cancer Metastasis Rev 2010; 29 (1): 207-222.
41. White TA, Kwon EM, Fu R, Lucas JM, Ostrander EA, Stanford JL, Nelson PS,. The Monoamine Oxidase A gene promoter repeat and prostate cancer risk. Prostate 2012; 72 (15): 1622-1627.
42. Kashiwagi E, Shiota M, Yokomizo A, Itsumi M, Inokuchi J, Uchiumi T, Naito S,. Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer. Prostate 2012; 72 (7): 741-751.
43. Nguyen HL, Zucker S, Zarrabi K, Kadam P, Schmidt C, Cao J,. Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase. Mol Cancer Res 2011; 9 (10): 1305-1318.